Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
CANCER:
Oral Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Head and Neck Cancer (574
)
Thyroid Gland Carcinoma (337
)
Squamous Cell Carcinoma of Head and Neck (252
)
Salivary Gland Cancer (50
)
Nasopharyngeal Carcinoma (48
)
Oropharyngeal Cancer (23
)
Tongue Carcinoma (4
)
Head and Neck Cancer (574
)
Thyroid Gland Carcinoma (337
)
Squamous Cell Carcinoma of Head and Neck (252
)
Salivary Gland Cancer (50
)
Nasopharyngeal Carcinoma (48
)
Oropharyngeal Cancer (23
)
Tongue Carcinoma (4
)
›
Associations
(51)
Heatmap
News
Twitter
Trials
Reset Filters
Veri cancer hierarchy
x
x
x
x
No biomarker
Oral Cancer
No biomarker
Oral Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 expression
Oral Cancer
PD-L1 expression
Oral Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
cisplatin + paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
cisplatin + paclitaxel + 5-fluorouracil
Sensitive
:
A2
cisplatin + paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
cisplatin + paclitaxel + 5-fluorouracil
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
methotrexate
Sensitive: A2 - Guideline
methotrexate
Sensitive
:
A2
methotrexate
Sensitive: A2 - Guideline
methotrexate
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
cisplatin + docetaxel
Sensitive: A2 - Guideline
cisplatin + docetaxel
Sensitive
:
A2
cisplatin + docetaxel
Sensitive: A2 - Guideline
cisplatin + docetaxel
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
carboplatin + paclitaxel
Sensitive
:
A2
carboplatin + paclitaxel
Sensitive: A2 - Guideline
carboplatin + paclitaxel
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
afatinib
Sensitive: A2 - Guideline
afatinib
Sensitive
:
A2
afatinib
Sensitive: A2 - Guideline
afatinib
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A2 - Guideline
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A2
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A2 - Guideline
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
cisplatin + paclitaxel
Sensitive: A2 - Guideline
cisplatin + paclitaxel
Sensitive
:
A2
cisplatin + paclitaxel
Sensitive: A2 - Guideline
cisplatin + paclitaxel
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
cisplatin + 5-fluorouracil
Sensitive
:
A2
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
cisplatin + 5-fluorouracil
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
5-fluorouracil + hydroxyurea
Sensitive: A2 - Guideline
5-fluorouracil + hydroxyurea
Sensitive
:
A2
5-fluorouracil + hydroxyurea
Sensitive: A2 - Guideline
5-fluorouracil + hydroxyurea
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
carboplatin + 5-fluorouracil
Sensitive: A2 - Guideline
carboplatin + 5-fluorouracil
Sensitive
:
A2
carboplatin + 5-fluorouracil
Sensitive: A2 - Guideline
carboplatin + 5-fluorouracil
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
pembrolizumab + cetuximab
Sensitive: A2 - Guideline
pembrolizumab + cetuximab
Sensitive
:
A2
pembrolizumab + cetuximab
Sensitive: A2 - Guideline
pembrolizumab + cetuximab
Sensitive
:
A2
GDF15 overexpression
Oral Cancer
GDF15 overexpression
Oral Cancer
TPF
Sensitive: C3 – Early Trials
TPF
Sensitive
:
C3
TPF
Sensitive: C3 – Early Trials
TPF
Sensitive
:
C3
POU5F1 overexpression + NANOG overexpression
Oral Cancer
POU5F1 overexpression + NANOG overexpression
Oral Cancer
cisplatin
Resistant: C3 – Early Trials
cisplatin
Resistant
:
C3
cisplatin
Resistant: C3 – Early Trials
cisplatin
Resistant
:
C3
miR-1290-L
Oral Cancer
miR-1290-L
Oral Cancer
5-fluorouracil
Sensitive: C3 – Early Trials
5-fluorouracil
Sensitive
:
C3
5-fluorouracil
Sensitive: C3 – Early Trials
5-fluorouracil
Sensitive
:
C3
KRAS mutation
Oral Cancer
KRAS mutation
Oral Cancer
cetuximab
Resistant: C3 – Early Trials
cetuximab
Resistant
:
C3
cetuximab
Resistant: C3 – Early Trials
cetuximab
Resistant
:
C3
PD-L1 overexpression
Oral Cancer
PD-L1 overexpression
Oral Cancer
nivolumab + MGCD516
Sensitive: C3 – Early Trials
nivolumab + MGCD516
Sensitive
:
C3
nivolumab + MGCD516
Sensitive: C3 – Early Trials
nivolumab + MGCD516
Sensitive
:
C3
PD-L1 overexpression
Oral Cancer
PD-L1 overexpression
Oral Cancer
olaparib
Sensitive: C3 – Early Trials
olaparib
Sensitive
:
C3
olaparib
Sensitive: C3 – Early Trials
olaparib
Sensitive
:
C3
PD-L1 overexpression
Oral Cancer
PD-L1 overexpression
Oral Cancer
pazopanib
Sensitive: C3 – Early Trials
pazopanib
Sensitive
:
C3
pazopanib
Sensitive: C3 – Early Trials
pazopanib
Sensitive
:
C3
PD-L1 overexpression
Oral Cancer
PD-L1 overexpression
Oral Cancer
paclitaxel
Sensitive: C3 – Early Trials
paclitaxel
Sensitive
:
C3
paclitaxel
Sensitive: C3 – Early Trials
paclitaxel
Sensitive
:
C3
PD-L1 overexpression
Oral Cancer
PD-L1 overexpression
Oral Cancer
docetaxel
Sensitive: C3 – Early Trials
docetaxel
Sensitive
:
C3
docetaxel
Sensitive: C3 – Early Trials
docetaxel
Sensitive
:
C3
CHEK2 mutation
Tongue Carcinoma
CHEK2 mutation
Tongue Carcinoma
ABT-888 + M6620
Sensitive: C4 – Case Studies
ABT-888 + M6620
Sensitive
:
C4
ABT-888 + M6620
Sensitive: C4 – Case Studies
ABT-888 + M6620
Sensitive
:
C4
FGFR2 P253R
Tongue Carcinoma
FGFR2 P253R
Tongue Carcinoma
cetuximab
Sensitive: C4 – Case Studies
cetuximab
Sensitive
:
C4
cetuximab
Sensitive: C4 – Case Studies
cetuximab
Sensitive
:
C4
FGFR2 P253R
Tongue Carcinoma
FGFR2 P253R
Tongue Carcinoma
pazopanib
Sensitive: C4 – Case Studies
pazopanib
Sensitive
:
C4
pazopanib
Sensitive: C4 – Case Studies
pazopanib
Sensitive
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
